Correvio Pharma (NASDAQ:CORV) Upgraded at ValuEngine

ValuEngine upgraded shares of Correvio Pharma (NASDAQ:CORV) from a sell rating to a hold rating in a research report sent to investors on Thursday, ValuEngine reports.

CORV traded down $0.28 during trading on Thursday, reaching $1.57. The stock had a trading volume of 690,748 shares, compared to its average volume of 84,915. The stock has a market capitalization of $75.89 million, a PE ratio of -1.76 and a beta of 0.44. The company has a current ratio of 2.80, a quick ratio of 2.42 and a debt-to-equity ratio of 7.21. Correvio Pharma has a one year low of $1.55 and a one year high of $5.24. The firm’s 50-day moving average is $2.08.

Correvio Pharma (NASDAQ:CORV) last released its earnings results on Wednesday, May 8th. The company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.04). The firm had revenue of $7.25 million during the quarter, compared to the consensus estimate of $7.91 million. Correvio Pharma had a negative net margin of 58.25% and a negative return on equity of 375.42%. On average, analysts forecast that Correvio Pharma will post -0.75 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in the company. Commonwealth Equity Services LLC increased its stake in shares of Correvio Pharma by 45.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 105,623 shares of the company’s stock valued at $228,000 after purchasing an additional 33,250 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in shares of Correvio Pharma by 1.1% in the 1st quarter. Westfield Capital Management Co. LP now owns 4,788,032 shares of the company’s stock valued at $15,130,000 after purchasing an additional 50,228 shares during the last quarter. Financial Counselors Inc. bought a new position in shares of Correvio Pharma in the 1st quarter valued at $116,000. ARS Investment Partners LLC increased its stake in shares of Correvio Pharma by 1.2% in the 1st quarter. ARS Investment Partners LLC now owns 337,868 shares of the company’s stock valued at $1,068,000 after purchasing an additional 4,013 shares during the last quarter. Finally, Columbia Pacific Advisors LLC increased its stake in shares of Correvio Pharma by 29.8% in the 1st quarter. Columbia Pacific Advisors LLC now owns 130,709 shares of the company’s stock valued at $413,000 after purchasing an additional 30,000 shares during the last quarter. 44.92% of the stock is currently owned by hedge funds and other institutional investors.

About Correvio Pharma

Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.

Further Reading: What is quantitative easing?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Correvio Pharma (NASDAQ:CORV)

Receive News & Ratings for Correvio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Correvio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.